Version: 1.0.0 | Published: 8 Oct 2024 | Updated: 229 days ago
Documentation
Description:
PHOENIX DDR/Anti-PD-L1 Trial: A pre-surgical window of opportunity and post-surgical adjuvant biomarker study of DNA damage response inhibition and/or anti-PD-L1 immunotherapy in patients with neoadjuvant chemotherapy resistant residual triple negative breast cancer.
Coverage
Spatial:
United Kingdom,England
Provenance
Temporal
Distribution Release Date:
17 August 2018
Start Date:
01 January 2019
Time Lag:
Variable
Accessibility
Access
Access Rights:
Please contact the publisher using Contact Point details provided.
Access Request Cost:
Not specified
Delivery Lead Time:
Not applicable
Data Controller:
The Institute of Cancer Research
Usage
Resource Creators:
In Progress
Format and Standards
Vocabulary Encoding Schemes:
LOCAL
Languages:
en
Formats:
In Progress